Joke Bilcke1, Albert Jan van Hoek, Philippe Beutels. 1. Center for Health Economic Research and Modeling Infectious Diseases (CHERMID); Vaccine and Infectious Disease Institute (Vaxinfectio); University of Antwerp; Wilrijk, Belgium.
Abstract
AIM: To assess the effectiveness and cost-effectiveness of a universal childhood varicella-zoster vaccination programme in Belgium (1) using the most recent Belgian data on varicella-zoster burden, (2) exploring different options for the timing of the second dose, (3) obtaining results with and without exogenous natural boosting, and (4) investigating the possible additional benefit of zoster booster vaccination for adults at age 50 or 60 y. METHODS: An extensively studied and improved dynamic model is used to estimate primary and breakthrough chickenpox and zoster cases over time. For a range of vaccination options, we compared the direct costs (health care payer perspective) and health outcomes (including Quality-Adjusted Life-Years (QALYs) lost) associated with chickenpox and herpes zoster. Estimates of social contact patterns, health care use, costs and QALY losses are almost exclusively based on Belgian databases and surveys. RESULTS AND CONCLUSIONS: If exogenous natural boosting exists, a net loss in QALYs is expected for several decades after implementing a universal chickenpox vaccination programme, due to an increase in zoster mainly in persons aged 50-80 y. This result holds also for scenarios that minimise or counteract the expected increase in zoster incidence (e.g. additional booster vaccinations in adults). However, if the boosting hypothesis is not true or if costs and QALYs are cumulated over at least 33 to more than 100 y after vaccination (depending on the assumptions made), different options for universal 2-dose vaccination against chickenpox in Belgium would be cost-effective at a vaccine price of €43/dose or lower.
AIM: To assess the effectiveness and cost-effectiveness of a universal childhood varicella-zoster vaccination programme in Belgium (1) using the most recent Belgian data on varicella-zoster burden, (2) exploring different options for the timing of the second dose, (3) obtaining results with and without exogenous natural boosting, and (4) investigating the possible additional benefit of zoster booster vaccination for adults at age 50 or 60 y. METHODS: An extensively studied and improved dynamic model is used to estimate primary and breakthrough chickenpox and zoster cases over time. For a range of vaccination options, we compared the direct costs (health care payer perspective) and health outcomes (including Quality-Adjusted Life-Years (QALYs) lost) associated with chickenpox and herpes zoster. Estimates of social contact patterns, health care use, costs and QALY losses are almost exclusively based on Belgian databases and surveys. RESULTS AND CONCLUSIONS: If exogenous natural boosting exists, a net loss in QALYs is expected for several decades after implementing a universal chickenpox vaccination programme, due to an increase in zoster mainly in persons aged 50-80 y. This result holds also for scenarios that minimise or counteract the expected increase in zoster incidence (e.g. additional booster vaccinations in adults). However, if the boosting hypothesis is not true or if costs and QALYs are cumulated over at least 33 to more than 100 y after vaccination (depending on the assumptions made), different options for universal 2-dose vaccination against chickenpox in Belgium would be cost-effective at a vaccine price of €43/dose or lower.
Entities:
Keywords:
Zostavax; age; chickenpox; cost-utility; shingles; time horizon; uncertainty
Authors: M Salleras; A Domínguez; N Soldevila; A Prat; P Garrido; N Torner; E Borrás; L Salleras Journal: Vaccine Date: 2011-09-01 Impact factor: 3.641
Authors: Mélanie Drolet; Marc Brisson; Myron J Levin; Kenneth E Schmader; Michael N Oxman; Robert W Johnson; Stéphanie Camden; James A Mansi Journal: Clin J Pain Date: 2010-10 Impact factor: 3.442
Authors: Fiona T Scott; Robert W Johnson; Mary Leedham-Green; Eleri Davies; W John Edmunds; Judith Breuer Journal: Vaccine Date: 2005-09-30 Impact factor: 3.641
Authors: G Elias; A Souquette; S Heynderickx; I De Meester; H Jansens; P Beutels; P Van Damme; E Smits; P G Thomas; V Van Tendeloo; B Ogunjimi Journal: Clin Exp Immunol Date: 2018-09-19 Impact factor: 4.330
Authors: Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme Journal: Clin Vaccine Immunol Date: 2014-01-15
Authors: Alies van Lier; Anna Lugnér; Wim Opstelten; Petra Jochemsen; Jacco Wallinga; François Schellevis; Elisabeth Sanders; Hester de Melker; Michiel van Boven Journal: EBioMedicine Date: 2015-08-08 Impact factor: 8.143
Authors: Oliver Damm; Bernhard Ultsch; Johannes Horn; Rafael T Mikolajczyk; Wolfgang Greiner; Ole Wichmann Journal: BMC Public Health Date: 2015-06-05 Impact factor: 3.295